Paul M. Sondel

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

This study identifies treatment-induced neutrophil states in tumors using single-cell multi-omics, showing ICAM1 as a marker of anti-tumor activity and potential biomarker for immunotherapy response.

The paper shows CD4 T regulatory cells can kill tumor cells through trogocytosis after immunocytokine treatment in a melanoma model.

This paper optimizes CRISPR/Cas9 AAV transduction for generating murine CAR-T cells with high efficiency and minimal toxicity, enabling in vivo persistence and pre-clinical testing.

This study examines how CD8 T cells with different metabolic profiles contribute to tumor cure in hot versus cold murine tumors using radio-immunotherapy.

The paper detects canine anti-human antibodies (CAHA) in dogs treated with hu14.18-IL2 immunocytokine, showing increased levels and binding inhibition post-treatment.

The paper evaluates how the functional avidity of anti-B7H3 CAR-T constructs relates to their ability to trigger effector function against tumors with varying antigen density.

This paper develops a bispecific antibody targeting GD2 and B7-H3 to improve tumor selectivity and reduce toxicity in GD2-positive tumors.

This paper shows that low-dose radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in neuroblastoma by improving tumor regression and immune response.

The paper introduces HERON, an R package for identifying immunogenic epitopes from ultradense peptide binding arrays across multiple samples.